American Society Of Hematology

New Mayo Clinic studies to be presented at American Society of Hematology meeting

December 9, 2019 sarah Jonas 0 Comments American Society Of Hematology, Cancer, Leukemia, Medical Research, Multiple Myeloma, Stem Cell

Mayo Clinic researchers will present findings at the American Society of Hematology Annual Meeting Dec. 7–10 in Orlando.
New Mayo Clinic studies to be presented include:
DNA analysis identifies elevated risk factor for myeloma in individuals of African ancestry
Study identifies more precise assessment measures for patients newly diagnosed with chronic lymphocytic leukemia
Researchers develop method to assess cancer-fighting cell therapy’s effectiveness

Research Results

Treatment with PD-1 inhibitor prior to stem cell transplant is safe, effective for patients with classic Hodgkin lymphoma, study finds

December 9, 2019 sarah Jonas 0 Comments American Society Of Hematology, American Society of Hematology Annual Meeting, Dana Farber Cancer Institute, Graft Versus Host Disease, Hodgkin Lymphoma, Lymphoma, stem cell tranplantation, Stem Cell Transplant

A new analysis shows that a donor stem cell transplant following treatment with an immune checkpoint inhibitor is generally safe and produces good outcomes for patients with Hodgkin lymphoma.

Research Results

Dana-Farber scientists present promising findings in multiple myeloma at ASH Annual Meeting

December 9, 2019 sarah Jonas 0 Comments American Society Of Hematology, American Society of Hematology Annual Meeting, Dana-Farber, Dana-Farber Cancer Institute, Multiple Myeloma

Results of studies on a novel agent to treat multiple myeloma and a combination therapy aimed at slowing the progression of a precursor myeloma condition are among reports being presented by Dana-Farber Cancer Institute investigators at the ASH Annual Meeting.

Research Results

Use of venetoclax in reduced-intensity transplant conditioning regimen in patients with high-risk myeloid cancers shows promise in early trial

December 7, 2019 sarah Jonas 0 Comments American Society Of Hematology, American Society of Hematology Annual Meeting, AML acute myeloid leukemia, Dana-Farber, Dana-Farber Cancer Institute, Leukemia, Stem Cell Transplant

For patients with high-risk myeloid cancers undergoing a donor stem cell transplant, adding the targeted drug venetoclax to a reduced-intensity drug regimen prior to transplant is safe and does not impair the ability of the donor cells to take root in recipients’ bodies, a study led by Dana-Farber Cancer Institute researchers suggests.

Research Results

Genomic features of AML in patients over age 60 can predict success of bone marrow stem cell transplant, research shows

December 7, 2019 sarah Jonas 0 Comments American Society Of Hematology, American Society of Hematology Annual Meeting, AML acute myeloid leukemia, ASH annual meeting, Dana Farber Cancer Institute, Dana-Farber, Dana-Farber Cancer Institute, Stem Cell Transplant

For older patients with acute myeloid leukemia (AML), the prospects for success of a stem cell transplant can often be predicted based on the particular set of genetic mutations within the tumor cells, investigators at Dana-Farber Cancer Institute and other research centers will report today at the ASH Annual Meeting.

Research Results

Lymphoma Patients May Have New Path to Remission, Even When CAR T Therapy Fails

December 7, 2019 sarah Jonas 0 Comments American Society Of Hematology, American Society of Hematology Annual Meeting, Ash, Lymphoma

A new, experimental immunotherapy can put patients with B-cell non-Hodgkin lymphoma (NHL) that is resistant to or has come back after multiple other therapies, including CAR T therapy, into remission.

Announcement

Moffitt’s Top Blood Cancer Research Highlighted at the American Society of Hematology Annual Meeting

December 4, 2019 sarah Jonas 0 Comments American Society Of Hematology, American Society of Hematology Annual Meeting, ASH annual meeting, Moffitt Cancer Center

Moffitt Cancer Center, a leader in the clinical care and research of blood malignancies, will present its top clinical research at the 61st American Society of Hematology Annual Meeting, Dec. 7-10 at the Orange County Convention Center in Orlando, Fla.